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Background. In a selected group of granulomatosis with polyangiitis (GPA) patients, disease is limited 
to the upper and/ or lower airways without organ- or life-threatening symptoms. The literature 
suggests that these patients can be treated successfully with trimethoprim/ sulfamethoxazole (T/S). 
However, data remain conflicting about its effectiveness. 
Aim. The aim of this study was to evaluate effectiveness and safety of T/S therapy. 
Design. Retrospective cohort study. 
Methods. We evaluated effectiveness and safety of T/S therapy in 55 patients with localised (n= 31) 
and early systemic (n= 24) GPA treated at our center between 1989 and 2013. 
Results. Fifty patients were treated with T/S monotherapy 800/160 mg twice daily and five received 
T/S as add-on to other immunosuppressive medication. With T/S therapy 36 patients (66%) attained 
remission. A relapse developed in 18 patients (50%) after a median disease free survival of 21 [IQR 
10-26] months. In 19 patients (34%) therapy failed, 14 patients had refractory disease and started 
additional immunosuppressive therapy, 5 patients stopped T/S due to adverse drug reactions, 
primarily rash and nausea. A CRP threshold of 12.5 mg/L, calculated from the ROC curve, yielded 
a sensitivity of 76.9% and specificity of 68.6% for therapy response. Below this threshold, 89% of 
patients (n=24) attained remission, whereas 11% had refractory disease (n=3). 
Conclusions. T/S therapy can induce remission in a substantial number of GPA patients with 
localised and early systemic disease. T/S can be considered as first-line therapy in these patients if 
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Background
Granulomatosis with polyangiitis (GPA) is an autoimmune disease causing granulomatous 
inflammation in the respiratory tract and systemic necrotizing vasculitis of the small to medium 
sized blood vessels. In the majority of patients antineutrophil cytoplasmic antibodies (ANCA) are 
present, mostly directed against proteinase 3 (PR3) and in the minority against myeloperoxidase 
(MPO) (1,2). 
Generalized disease with widespread inflammation is often preceded by an initial phase of localised 
or early systemic disease. However, in approximately 5% of patients, GPA will remain confined to the 
respiratory tract without the development generalized disease during long-term follow-up (3,4).
Several case-reports and small series have demonstrated that trimethoprim/sulfamethoxazole 
(T/S) monotherapy can successfully induce remission in this selected group of patients, including 
one prospective study (5-8). However, others report poor effectiveness with T/S monotherapy (3). 
Patients treated with T/S will not be exposed to the side-effects of standard immunosuppressive 
induction therapy, comprising cyclophosphamide, rituximab or methotrexate in combination with 
glucocorticoids (9). T/S could be an attractive alternative for these patients. 
Data are scarce on the effectiveness of T/S monotherapy. Therefore, the objective of this study was 
to analyse the effectiveness and safety of T/S as induction therapy for patients with localised and 
early systemic GPA. 
Patients and methods
Patients 
All consecutive patients treated with T/S monotherapy or as add-on for the induction of remission 
of newly diagnosed and relapsing GPA in the University Medical Center Groningen between 1989 
and 2013 were included in this retrospective cohort study. Patients were classified as having GPA 
according to definitions adopted from the Chapel Hill Consensus Conference Nomenclature and 
the algorithm developed by Watts et al (1,10). Patient and clinical characteristics were collected 
from medical records. For this study no formal IRB approval was required. Patients who attained 
remission were followed until a relapse developed, death or lost to follow-up, whichever came first. 
Treatment
Induction therapy was T/S 800/160 mg twice daily for at least 2 years. One minor (11 years) received 
600/120 mg daily. Most patients with episcleritis received additional local therapy. Patients on 
low dose maintenance immunosuppressive therapy after generalized diseased, who developed 
a localised or early systemic relapse were also included, provided that the immunosuppressive 
therapy was not changed, making it plausible that the observed outcome was attributable to T/S. 
T/S was stopped in consultation with the patient after two years.
Measures
Disease activity at diagnosis was scored using the Birmingham Vasculitis Activity Score (BVASv.3) 
(11). ANCA were detected by indirect immunofluorescence and through antigen specific enzyme-






Localised disease was defined as GPA confined to the ENT tract or lungs without vasculitis outside 
these regions, without threatening vital organ functions and serum creatinine <120 μmol/L. Patients 
who only experienced malaise as a constitutive symptom in addition to ENT or pulmonary symptoms 
were classified as localised disease. Early systemic disease was defined as GPA involving the ENT 
tract or lungs and systemic vasculitis outside these regions without threatening vital organ functions 
and serum creatinine <120 μmol/L. In addition, to be considered for therapy with T/S  only, signs of 
active renal (erythrocyturia > 25/ul, proteinuria, change in renal function) or peripheral neurologic 
involvement (sensible/motoric neuropathy) had to be absent. Generalized disease was defined as 
systemic vasculitis outside the ENT tract and lungs, and with threatening vital organ functions, but 
serum creatinine <500 μmol/L, whereas severe disease was accompanied by organ failure or serum 
creatinine >500 μmol/L. These definitions were adopted from the EUVAS study group (12).  
Effectiveness of T/S therapy was defined by induction of remission (BVAS=0). Refractory disease was 
defined as persistent or increased disease activity necessitating immunosuppressive medication. 
A relapse was defined as the worsening, or new onset of disease activity attributable to active 
inflammation. Adverse drug reactions were defined as symptoms or signs possible attributable 
to, and occurring after the start  of T/S, and improving after discontinuation of T/S. Nasal swabs 
were performed in patients during follow-up. Patients with at least two cultures testing for 
Staphylococcus aureus (S. aureus) were considered persistent carrier when all tested positive for 
S. aureus, patients were considered non- carrier when none tested positive, and the remaining 
patients were considered intermittent carriers.    
Statistics
Statistical analysis were performed using SPSS 22.0 and GrapPad Prism (version 5.00). Parametric 
data are reported as mean and standard deviation (SD) and nonparametric data as median and 
interquartile range [IQR]. Differences between groups were tested using the Student’s T-test, 
Mann-Whitney U or the Fisher’s exact test as appropriate. Disease free survival was calculated 
using Kaplan-Meier curves with log-rank testing. Receiver operating characteristics (ROC) showing 
sensitivity and 1- specificity were used to determine cut-off levels of CRP with significant difference 
between therapy outcome. Sensitivity reflects the proportion of patients with refractory disease 
and high CRP, whereas specificity reflects the proportion of patients with remission and low CRP. 
The optimal cut-off value was determined by the Youden index (13). A two-sided p value of < 0.05 
was considered statistically significant. 
Results
Patient characteristics 
Fifty-five GPA patients were included in this study. Twenty-seven presented with localised disease 
and 20 with early systemic disease at diagnosis. Four presented with a localised relapse and four 
with an early systemic relapse. Five out of eight relapsing patients received immunosuppressive 
therapy at the time of presentation. Two received low dose (≤10mg) prednisolone, one received 
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flowchart of all assessed (n= 644) and eligible patients is shown in supplementary figure 1.
The median follow-up was 10 [IQR 4-14] years, with a total follow up of 564 patient years. Baseline 
characteristics of all participants are shown in table 1. Symptoms of disease activity at start of T/S 
therapy are shown in supplementary table 1. 
Table 1. Baseline characteristic of all included patients. 
Age (years)   49 (18)
Sex (female), n (%)   33 (60%) 
T/S therapy for diagnosis/ relapse, n 47/8
Diagnostic histology, n   35 (64%)
BVAS    7 [6-8]
  Localised disease   6 [6-7] (n=31)
  Early systemic disease  8 [6-10] (n= 24)
ANCA staining IF, titre at diagnosis  1:80 [1:40; 1:160]
  cANCA, n    1:80 [1:80-1:160], n=38
  pANCA, n    1:160 [1:80-1:320], n= 10
  Atypical/ negative ANCA, n  n= 5/ n=2
ANCA specificity 
  Anti-PR3, n   39
  Anti-MPO, n   8
  Negative, n   8
S. aureus, n 
  Positive    24
  Negative    21
  Not tested   10
CRP (mg/L) 11 [3-17]
Hemoglobin (mmol/L)   8.2 (0.8)
Serum creatinine (µmol/L)  85 (20)
MCV (fL)    87.2 (5.0)
Abbreviations: SD: standard deviation; T/S: trimethoprim/sulfamethoxazole; BVAS: 
Birmingham Vasculitis Activity Score; ANCA: antineutrophil cytosplasmic antibodies; 
IF: immunofluorescence;Anti-PR3: anti-proteinase 3; Anti-MPO: anti-myeloperoxidase; 
IQR: interquartile range; S. aureus: Staphylococcus aureus; CRP: C-reactive protein; 
MCV: mean corpuscular volume 
Characteristics   n= 55
Effectiveness 
Remission was induced in 36 patients (65.5%). Fourteen patients (25,5%) had refractory disease 
and five patients (9%) discontinued therapy due to T/S -related adverse drug reactions. T/S as add-
on induced remission in four patients (80%), and one patient (20%) had refractory disease. Median 
time to remission was 14 weeks [IQR 11-20] (figure 1). 
Treatment was switched in patients with refractory disease after a median time of 14 weeks [IQR 
3-36]. In eight patients with refractory disease there was no or insufficient reduction of symptoms 
and in six there was progression of disease. The majority of patients were subsequently treated 





Table 2. Therapy and outcome after refractory disease with trimethoprim/sulfamethoxazole monotherapy. 
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of treatment; 1 persistent ENT 
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Abbreviations: CY: cyclophosphamide; AZA: azathioprine; MTX: methotrexate; ENT: ear- nose and throat 
Cyclophosphamide (n= 4) and CY and 
maintenance AZA (n= 4) or MTX (n=1)
Methotrexate and glucocorticoids
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Figure 1. Time to remission after start of 
trimethoprim/sulfamethoxazole. 
Of note, one 86 year old patient improved clinically with T/S therapy until three months later rapidly 
progressive glomerulonephritis developed. Prompt immunosuppressive therapy could not induce 
remission. The patient died of combined renal failure, malnutrition, a gastro-intestinal bleeding, 
and infections of the respiratory and urinary tract. 
 
Predictors of therapy outcome 
We investigated predictors associated with therapy outcome (table 3). Patients who attained 
remission had a significantly lower CRP at start of treatment compared to patients with refractory 
disease (8 mg/L [IQR <3-17] vs. 15 mg/L [IQR 13-79]; p= 0.007). The area under the ROC curve for 
CRP and therapy response (remission or refractory disease) was 0.754 ([95% CI 0.600- 0.908], p= 
0.007, figure 2). The optimal cut-off value was 12.5 mg/L with a sensitivity of 76.9%, a specificity of 
68.6%, and a Youden Index of 0.455. Remission was attained in 89% of patients with CRP ≤12.5 mg/L 
(n= 24), whereas 11% had refractory disease (n=3). In contrast, 52% of patients with CRP >12.5 
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Table 3. Patients with refractory disease and remission.
Newly diagnosis, n (%) 13 (93%)  29 (81%)  0.414
Histological confirmation  9 (64%)  23 (64%)  1.000
  of diagnosis, n (%)
Localised disease, n (%) 7 (50%)  16 (44%)  0.761
CRP (mg/L) 15 [13-79]  8 [<3-17]  0.007
ANCA positive(IF)   11 (85%)   29 (81%)  1.000
at diagnosis, n (%) n=13, 1 missing  
Anti-PR3 positive  11 (79%)  24 (67%)  0.507
  at diagnosis, n (%)
S. aureus positive  4 (36%)  16 (57%)  0.301
  before start 
T/S, n (%) n= 11, 3 missing n= 28, 8 missing
Characteristics Refractory disease   Remission  p
 (n= 14)   (n= 36) 
Abbreviations T/S: trimethoprim/sulfamethoxazole; vs: versus; CRP: C-reactive protein; IQR: 
interquartile range; ANCA: antineutrophil cytosplasmic antibodies; IF: immunofluorescence; anti-
PR3: proteinase 3; S. aureus: Staphylococcus aureus; UMCG: University Medical Center Groningen
Staphylococcus aureus 
Forty patients had at least two nasal cultures for S. aureus during remission induction. Fifteen 
patients (37,5%) were non-carriers, 21 (52,5%) intermittent carriers and 4 (10%) persistent carriers. 
These differences did not affect remission rate (Figure 3). Resistance to T/S therapy developed in at 
least four patients during the remission induction phase, of whom three attained remission. 
Figure 2. ROC curve for CRP and therapy outcome: 
remission or refractory disease. The Youden Index 
optimum indicates a sensitivity of 76.9% and 
specificity of 68.6%.  




















Eighteen of the 36 patients in remission did not develop a relapse until the end of follow-up, with 
a median follow-up of 151 [IQR 54-165] months. Fifty per cent of patients relapsed after a median 
disease free survival of 21 [IQR 10-26] months. Eleven relapses occurred during T/S use. Five 
relapses were localised, nine early systemic, two generalized and two severe. Disease free survival 
was similar for patients with localised disease and early systemic disease (p= 0.717). 
Adverse drug reactions 
T/S-related adverse drug reactions occurred in 12 patients and consisted primarily of nausea and 
rash, which were transient in most (supplementary table 2). However, therapy had to be stopped in 
five patients before remission could be attained. All adverse reactions were reversible within 1 day 
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Figure 4. Disease stage at the end of follow-up, including median and interquartile range of follow-up in months.
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As expected, serum creatinine and mean corpuscular volume significantly increased and hemoglobin 
significantly decreased after the start of T/S. These effects were small, did not necessitate therapy 
adjustment and were reversible after discontinuation of therapy (data not shown). 
Disease progression and mortality 
Disease stage at the end of follow-up for newly diagnosed patients is shown in figure 4. This includes 
patients with refractory disease and progression, who developed early systemic (n=1); generalized 
(n=3) and severe disease (n=2) shortly after diagnosis. 
Twelve patients died during follow up. One patient died of exacerbated GPA 4 months after start 
of therapy, as described above. One patient died of a relapse 19 months after T/S therapy. Four 
patients died of treatment-related comorbidity, especially cyclophosphamide-related; 2 urothelial 
cell carcinoma (230, 245 months after start T/S), 1 myelodysplastic syndrome (223 months after 
start T/S), 1 systemic varicella-zoster virus infection (61 months after start T/S). All 4 patients had 
received one or more courses of cyclophosphamide and other immunosuppressive therapies in 
addition to the disease episode treated with T/S. One patient died 174 months after start of T/S of 
a squamous cellular carcinoma. Five patients died of unrelated causes after a median period of 94 
months [IQR 86- 97] after therapy. 
Discussion
This study showed that trimethoprim/sulfamethoxazole therapy can successfully induce long-term 
remission in approximately two-third of patients with localised and early systemic GPA in a cohort of 
consecutive patients. The remission rate was substantially higher, up to 89%,  in patients with CRP 
less than 12.5 mg/L at start of therapy. CRP as a reflection of systemic inflammation appears to be 
a good predictor of therapy success and a better predictor than disease stage. A similar percentage 
of patients with localised and early systemic disease attained remission. 
In the literature the reported effectiveness of T/S monotherapy varies widely with some reports 
showing an insufficient response in 73%, whereas others show improvement in 58% up to 93% 
of patients (3,5,8,14). These contradicting results might be explained by various factors; most 
reported studies are small, different definitions of remission or improvement are used and cohorts 
are heterogeneous. In addition, one of the biggest challenges is to await the therapeutic effect of 
T/S. In half of the patients remission can be expected after three to four months, but can take up to 
5 or 6 months in some. This requires considerable patience of both patient and treating physician 
and necessitates close clinical monitoring for signs of disease progression during this period. 
Fifty per cent of patients in remission relapsed, most within two years after induction of remission. 
This is in accordance with the relapse rate found by Holle et al. and similar as the relapse rate 
described in patients with generalized disease (3,15). 
T/S monotherapy could be regarded a safe therapy. All adverse drug reactions were quickly 
reversible and almost all patients with refractory disease reached remission after switching to 
immunosuppressive therapy. Still, close monitoring remains necessary. 
Finally, we showed that of all assessed GPA patients an estimated percentage of 4% (27/ 644) 
presents with localised disease, which is consisted with literature (3,4,16). In our study more patients 





generalized disease within one year, in contrast to the studies of Pagnoux et al and Holle et al (3,4). 
In addition, we had an extensive follow-up of ten years, compared to 58 months and 4 years in both 
before mentioned studies, respectively.  
Researchers have already speculated about an etiological role of infections in the development of 
GPA for many years. This is indirectly supported by studies showing reduced incidence of relapses 
with T/S therapy (17,18). With ensuing research, several microbes and viruses have been suggested 
to cause or worsen the course of disease (19-22). Up to now, the role of S. aureus has been the 
most convincing and various mechanisms by which S. aureus induces or exacerbates GPA have 
been proposed (23). For example, through super antigens of S. aureus which promote extensive 
T-cell proliferation, priming of neutrophils or by S. aureus derived cationic enzymes such as acid 
phosphatase, which bind to endothelial cells and might induce glomerulonephritis (24). However, 
the exact mechanism has yet to be elucidated. 
Considering the evidence linking bacteria to the course of GPA, the use of an antimicrobial agent, 
such as T/S seems rational. However, it has been hypothesized that this folate antagonist similar 
to other sulfonamides and sulfones not only possess antimicrobial properties, but also exerts an 
anti-inflammatory effect (25). This has been supported by in vitro studies showing inhibition of the 
myeloperioxidase (MPO)-hydrogen peroxide-halogen (MHPH) system of neutrophils. Inhibition of 
the MHPH system diminishes the generation of reactive oxygen species and lysosomal enzymes 
(26). These are necessary for effective phagocytosis in situations of infections, but cause tissue 
destruction and macromoleculair alterations such as antiproteinase inactivation in normal tissue 
(27). This is an interesting mechanism of action, especially in a disease such as GPA in which 
neutrophils are thought to play a central role. We did not find evidence that T/S acts merely trough 
eradication of S. aureus since, persistent non-carriers, persistent carriers and patients with a S. 
aureus strain resistant to T/S attained remission. The potential anti-inflammatory properties of T/S 
are interesting for further research. 
Obviously, our study has a number of limitations. This is a retrospective cohort study. It might be 
questioned whether all patients without diagnostic histology had GPA. Patients were diagnosed 
using the Chapel Hill Consensus nomenclature and the algorithm of Watts, which means that 
patients with histology compatible with GPA needed additional signs or symptoms, like a positive 
ANCA in ELISA (1,10). The assessment of treatment effectiveness is challenging, especially due to the 
considerable period of time before a treatment effect can be observed. The EULAR recommends to 
assess treatment effectiveness after a predetermined period of time (28). For T/S this has yet to be 
determined, but should until than be patient-tailored during close monitoring. Selection bias might 
have occurred, since the UMCG is a tertiary referral center. We therefore do not think our results to 
be overestimated. Unfortunately, our cohort is underpowered for extensive analyses; however it is 
a fairly large cohort with extensive follow-up in comparison with other studies in literature.  
Conclusion
In conclusion, trimethoprim/sulfamethoxazole monotherapy might be considered a first-line therapy 
in patients with localised or early systemic GPA if at presentation CRP is low. Ideally a multicenter 
prospective study would confirm our results and determine the optimal treatment of this small 
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Supplementary figure 1. Flowchart of all assessed and analysed patients. 
Assessed for eligibility (n=644)
Excluded (n=589)
 Generalized disease (n=577)
 Not meeting Chapel Hill consensus  
 criteria or algorithm of Watts (n=5)
 Cocaine-induced vasculitis (n=2)
 Insufficient documentation (n=5)
Analyzed (n=55)
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Supplementary table 1. Disease activity at start of trimethoprim/sulfamethoxazole therapy 
and therapy outcome.
  Therapy outcome 
  Cohort Rem. Ref. dis. SE
Total number  55 36 14 5
Localised disease    
Nasal symptoms* (+ malaise)  13 (+11) 10 (+6) 1 (+3) 2 (+2)
Hearing loss, malaise, nasal symptoms,   1 1 0 0  
Hearing loss, conductive hearing loss malaise   1 0 1 0
Hearing loss, malaise, nasal symptoms,   1 0 1 0
  significant subglottic inflammation 
Significant subglottic inflammation,  2 2 0 0
  hoarseness stridor, nasal symptoms  
Malaise, nasal symptoms, hoarseness   1 0 1 0
  stridor, cough, dyspneu or wheeze 
Nodules fibrosis, haemoptysis  1 1 0 0
Early systemic disease    
Nasal symptoms +    
  Malaise, arthralgia/arthritis (MA)  3 3 0 0
  Hearing loss, MA/ fever (≥ 38.5˚C)  2 0 0/1 1/0
  Headache, weight loss (≥2 kg)    1 0 1 0
  Malaise, fever (<38.5 ˚C)    1 1 0 0
Lung infiltrate, nasal symptoms +    
  MA, weight loss ≥2 kg    1 1 0 0
  Malaise, weight loss ≥2 kg, cough  1 0 1 0
  Arthralgia/arthritis, dyspneu/ weeze,  1 1 0 0
Other skin vasculitis, nasal symptoms +   1 1 0 0
  MA     1 0 1 0
  Malaise, episcleritis    1 0 1 0
Episcleritis +    2 2 0 0
  Nasal symptoms, MA   1 1 0 0
  Nasal symptoms, mouth ulcer    1 1 0 0
Conjunctivitis, arthralgia/arthritis, nasal symptoms 1 1 0 0
Conjunctivitis, blurred vision, infiltrate malaise  1 0 1 0
Dacryocystitis     1 1 0 0
Cutaneous ulcer    1 1 0 0
Significant proptosis (+ blurred vision)  2 1 0 (+1) 0
Haematuria, arthralgia/arthritis, nasal symptoms  1 1 0 0
Abbreviations: Rem.: remission; Ref. dis.: refractory disease; SE: side-effects; MA: malaise and 
arthralgia/ arthritis. *Nasal crusting, bloody nasal discharge, crusting and sinus involvement are 





 Supplementary table 2. Side-effects of trimethoprim/sulfamethoxazole therapy.
Male  Nausea Stopped after 3 weeks
Male  Nausea, rash Stopped after 2 weeks
Female  Fever, rash, itch Stopped after 1 week
Male  Rash, itch Stopped after 2 weeks
Female  Erythematous papular lesions,  Stopped after 4 days
 perivascular inflammatory 
 infiltrate, leucopenia, myalgia 
Female  Transient nausea  Continued
Female  Transient rash and itch Continued
Male Transient diarrhoea  Continued
Female  Transient nausea Continued
Male  Rash Stopped after 2 years
Male  Rash Stopped after 2 years 9 months
Female Dubious abdominal pain*  Stopped after 7 years  
Patient Symptoms Therapy stopped or continued
*Dubious side-effect since the relation with trimethoprim/ sulfamethoxazole could not univocally 
be proven.
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